Overview

Tranexamic Acid in Cyanotic Heart Defects

Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
0
Participant gender:
All
Summary
The use of antifibrinolytic agents such as to reduce blood loss in congenital cardiac surgery has been described in many studies
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Assiut University
Treatments:
Tranexamic Acid
Criteria
Inclusion Criteria:

2 to 12 years cyanotic cardiac disease with cardio pulmonary bypass

Exclusion Criteria:

Previous cardiac surgery any operation within 48 hr., previous inotropes or mechanical
vention aprotinin exposure Liver or renal impairment Coagulation or hemostatic dysfunction
within the last 7 days before surgery.